Skip to content

Study on rapid tranquilization: comparison of intramuscular olanzapine and intramuscular haloperidol

Rapid tranquillization of agitated or aggressive patients in an in-patient psychiatric setting: Pragmatic randomized double-blind trial of intramuscular olanzapine versus intramuscular haloperidol

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2011/013
Enrollment
134
Registered
2011-11-28
Start date
2011-12-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric conditions

Interventions

Eligible participants would be randomized to receive either intramuscular haloperidol (5-10 mg) or intramuscular olanzapine (10 mg). All doses would be at the discretion of the attending doctor and wi

Sponsors

Dr Varuni de Silva,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years 2. Patients admitted with acute agitation or already hospitalized and become agitated with a total score of Positive and Negative Symptoms Scale-Excited Component (PANSS-EC) >= 14 or at least one item with a score of >= 4 (If this requirement is not met at baseline and rapid tranquilization has not been given the patient could be re-evaluated in the subsequent 24 hours) 3. Clear indication of intramuscular route of administration according to the attending doctor because of agitation, aggression, or violent behaviour 4. Presence of good physical health confirmed by medical history and physical examination

Exclusion criteria

Exclusion criteria: 1. Agitation primarily due to acute intoxication 2. History of drug or alcohol dependence in the previous 8 weeks 3. Use of benzodiazepines / other hypnotics/ oral or intramuscular antipsychotic in the 4 hours before study intervention 4. Use of depot antipsychotic within one dose interval before study intervention 5. Clinically significant acute or chronic pulmonary disease/ clinically significant hepatic, renal, gastroenterological, cardiovascular, neurological or hematological disease 6. Pregnant or lactating females

Design outcomes

Primary

MeasureTime frame
Positive and Negative Symptoms Scale – Excited Component (PANSS–EC) [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Clinical Global Impression Scale (CGI) [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Agitation Calmness Evaluation Scale (ACES) [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention ] Overt Aggression scale (OAS) [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention ]

Secondary

MeasureTime frame
Proportion of patients requiring medical attention due to continued agitation [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Proportion of patients requiring physical restraining [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Proportion of that needed additional medication [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Extrapyramidal side effects with Simpson Angus Extrapyramidal symptom scale and Barnes akathisia scale [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention] Vital signs (heart rate, respiratory rate,systolic and diastolic blood pressure) [At baseline, 15 minutes, 30 minutes, 60 minutes and 120 minutes after intervention]

Countries

Sri Lanka

Contacts

Public ContactDr Hiranya Wijesundara

Senior Registrar in Psychiatry

hiranya.w@gmail.com

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026